| ￥2600 | |
| Z05005-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 11.5 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Measured by its ability to inhibit BMP9 induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is <50 ng/mL in the presence of 2 ng/mL of recombinant human BMP9 (Cat.GDF-HM002). »
Immobilized Human GDF-2, No Tag at 2 μg/ml (100 μI/well) on the plate. Dose response curve for ALK-1/Activin RL1, His, Human, His Tag with the EC50 of 6.6ng/ml determined by ELISA. »
The purity of ALK-1/Activin RL1, His, Human is greater than 95% as determined by SEC-HPLC. »
ALK-1/Activin RL1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence. |
| Synonyms | ACVRLK1; ORW2; ALK1; ALK-1; EC 2.7.11; HHT; HHT2; SKR3; TSR-I; ACVRL1; Activin RLI |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
